Phio Pharmaceuticals gets SMC nod to advance PH-762 skin cancer trial to fifth cohort

Phio Pharmaceuticals Corp.

Safety Monitoring Committee recommends dose escalation to fifth (final) cohort in Phase 1b trial of INTASYL PH-762.
No dose-limiting toxicities, serious adverse events, or clinically relevant treatment-emergent reactions in fourth cohort (5 patients).
To date, 15 patients treated; pathological complete response (100% clearance) seen in 4 of 9 cSCC patients from prior cohorts.
Enrollment in final cohort expected to complete in Q3 2025.
PH-762 is an intratumoral siRNA targeting cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.